KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Debt (2016 - 2025)

Historic Total Debt for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $1.1 billion.

  • Sarepta Therapeutics' Total Debt fell 1274.19% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 1274.19%. This contributed to the annual value of $1.1 billion for FY2024, which is 814.82% down from last year.
  • Sarepta Therapeutics' Total Debt amounted to $1.1 billion in Q3 2025, which was down 1274.19% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Total Debt ranged from a high of $1.5 billion in Q4 2022 and a low of $1.1 billion during Q3 2025
  • For the 5-year period, Sarepta Therapeutics' Total Debt averaged around $1.2 billion, with its median value being $1.1 billion (2025).
  • Its Total Debt has fluctuated over the past 5 years, first surged by 5860.24% in 2021, then plummeted by 1983.54% in 2023.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Total Debt stood at $1.1 billion in 2021, then surged by 40.79% to $1.5 billion in 2022, then fell by 19.83% to $1.2 billion in 2023, then decreased by 8.15% to $1.1 billion in 2024, then decreased by 5.8% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.